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For patients with locally advanced esophageal cancer no clear standard of care exists.
Notwithstanding several negative phase III studies the data provide support for so-called
trimodality treatment and this is probably the most common approach. Even the role of
surgery has been questioned.These alternative approaches are set against a changing epi-
demiological background whereby adenocarcinoma has become the predominant tumor
type, at least in the western world. In recent times an emphasis has been placed on the
better selection of patients, predominantly based on data that shows a markedly improved
survival in those who exhibit a response to neo-adjuvant therapy. In this article we review
the major studies and discuss new approaches to the management of patients with locally
advanced cancer of the esophagus.
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INTRODUCTION
Cancer of the esophagus is a disease in transition, at least in terms
of its epidemiology. The “fundamentals” of esophageal cancer –
in terms of its epidemiology and anatomical distribution – have
changed in the recent past (at least in the “western” world). These
“fundamentals” have by contrast remained relatively static for
other solid tumors. Over the past 20 years esophageal cancer has
changed from being a so-called“blue collar”disease (Bollschweiler
et al., 2000) of predominantly squamous pathology affecting the
mid andupper esophagus to being a disease of the lower esophagus
of glandular pathology affecting an increasing number of females.
Any review of this disease must be placed in the context of this
changing epidemiology.
EPIDEMIOLOGY
Esophageal cancer is diagnosed in approximately half a million
people worldwide annually and is the eighth leading cause of can-
cer death worldwide (Kamangar et al., 2006). Its generally poor
outlook is reﬂected in a high mortality-to-incidence rate ratio of
0.83 (compared to 0.51–0.52 in colorectal cancer for example). In
the last decade, there has been only a modest improvement in the
5-year survival rate (Siegel et al., 2011). Historically, esophageal
cancer was predominantly of squamous pathology. In the 1970s
adenocarcinoma was reported as accounting for as low as 4% of
the disease burden (Bosch et al., 1979). For the US and other
“western” countries this has changed over the past 20 years such
that in the US and some northern European countries adeno-
carcinoma represents the predominant histological subtype (Blot
and McLaughlin, 1999; Bosetti et al., 2008; Umar and Fleischer,
2008). The greater part of this increase has occurred inwhitemales
however a signiﬁcant increase has also been seen in females and
across racial categories (Bollschweiler et al., 2001; Brown et al.,
2008). This is not a global phenomenon since in Asian coun-
tries squamous cell carcinoma (SCC) of the esophagus remains
predominant (Shibata et al., 2008). There are also marked ethnic
variations within geographic areas (Trivers et al., 2008).
The histologic categorization (squamous vs. adenocarcinoma)
does not in itself dictate the therapeutic choice at the present
time. However, as will be discussed the relative importance of
surgery and chemoradiation (CRT)may be different dependent on
pathology. At a minimum the epidemiological trend has impacted
indirectly the ﬁeld in that it has been paralleled by changes in
anatomical location. In contrast to SCC, which arises from the
upper esophagus, adenocarcinoma tends to arise from Barrett’s
dysplasia in the lower esophagus or gastro-esophageal (GE) junc-
tion. The mode of presentation may be different also in that fewer
than half of those with adenocarcinoma present with the “classic”
symptomatology of dysphagia and weight loss (Gibbs et al., 2007).
Fromapublic health standpoint both entities have overlapping but
different risk factor proﬁles which would require different preven-
tive strategies (Trivers et al., 2008). For example, obesity appears
to be a risk factor for adenocarcinoma but not squamous cancer
(Lagergren et al., 1999), whereas there has been a conﬂicting data
regarding the role of high risk HPV infection in the development
of SCC (Dillner et al., 1995; Kato et al., 2011).
STAGING
Recently, several changes were adopted in the seventh edition of
the American Joint Committee on Cancer (AJCC) tumor, node,
metastasis (TNM) staging system in esophageal cancer (Edge and
Compton,2010). The threemajor changes are: (1) The inclusion of
tumors at the esophagogastric junction and proximal 5 cm of the
stomach that extend into the EGJ or esophagus as esophageal can-
cers. (2) The development of separate stage grouping based on the
histology of the tumor (SCC vs. adenocarcinoma). (3) The classiﬁ-
cation of T4 disease based on the resectability of the tumor and its
relation to the adjacent organs. Accordingly, in tumors that invade
adjacent structures, such as pleura, pericardium, or diaphragm
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(T4a) surgery may still have a role. In contrast, T4b tumors that
involve the trachea, aorta, or vertebral body are considered unre-
sectable. Locally advanced cancer of the esophagus, deﬁned as
stage IIb to IIIc, includes tumors that invade regional lymph
nodes (N1-3) or local structures (T4 disease). Patients within this
category may be resectable, inoperable for medical reasons, or
technically unresectable for reasons of local tumor extension. As
will be discussed a loco-regional approach (i.e., chemoradiation)
with curative intent is still indicated for these latter two patient
groups. For disease that is not loco-regionally conﬁned (i.e., stage
IV, metastatic disease) systemic chemotherapy forms the major
part of therapy and local measures directed toward the esophagus
are palliative in intent.
ROLE OF PET
A recurring theme encountered in the neo-adjuvant studies men-
tioned above is that responders have a superior outcome to non-
responders. Identifying non-responders early in the course of their
neo-adjuvant therapy has the potential to allow them to go directly
to surgery (or alternatively to consider different chemotherapy).
In addition to its potential role as a“biomarker” in the early identi-
ﬁcation of non-responders PET scanning at baseline will uncover
metastatic disease in∼15%(Downey et al., 2003).Although it’s not
clear what relevance the initial absolute SUV value has (Shenﬁne
et al., 2009), decreases in SUV in response to neo-adjuvant therapy
appear to predict for improved survival outcomes (Downey et al.,
2003). An elevated SUV at baseline may also predict for likelihood
of response (Rizk et al., 2009).
The feasibility of so-called PET-directed therapy was evalu-
ated by Lordick et al. (2007) in a phase II (“MUNICON”) study
where 119 patients with adenocarcinoma of the esophago-gastric
junction underwent PET scanning 2weeks into their neo-adjuvant
chemotherapy to evaluate metabolic response (deﬁned as a reduc-
tion of SUV by ≥35%). Non-responders were taken directly to
surgery and had a median survival of 25.8months. Approximately
half the patients responded and continued on chemotherapy, 96%
of whom underwent R0 resection (compared to 74% in the non-
responders). The median survival for the PET-responders was
not reached at the time of report. A reﬁnement of this approach
was the MUNICON-2 study by the same group of investigators,
again in adenocarcinoma of the esophago-gastric junction, where
non-responders (identiﬁed by PET at 2weeks) received “salvage”
chemoradiation (Lordick et al., 2008). Unfortunately the majority
of these non-responders (>80%) showed no evidence of response
to this chemoradiation at a subsequent PET scan and only 69%
underwent an R0 resection with a median survival of 13.8months.
While it appears therefore that PET-directed therapy may prevent
patients fromreceiving a full course of neo-adjuvant therapy that is
not beneﬁting them, it is not clearwhether it will steer them toward
therapy that will alter their inferior prognosis. Furthermore, a
recent retrospective study questioned if post chemoradiotherapy
PET scan response, characterized as post treatment (SUV) of ≤3,
can predict the need for surgery. In this study 105 patients with
stage I-IVA esophageal cancer, mainly adenocarcinoma, received
trimodality therapy (55 patients) or chemoradiation therapy only
(50 patients). The PET-responders on the chemoradiation cohort
had longer 2-year overall survival (71 vs. 11%,P < 0.01) compared
to the non-responders and 2-year freedom from local failure was
also longer (75 vs. 28%,P < 0.01).On theother hand,nodifference
in outcome was noted between responders and non-responders
in patients who underwent surgery possibly because FDG-PET
residual disease was resected (Monjazeb et al., 2010).
TREATMENT OF LOCALLY ADVANCED ESOPHAGEAL CANCER
Surgery has been the historical mainstay for resectable, localized
esophageal cancer, and surgical resection remains the major ther-
apeutic modality today. However, unlike most other solid tumors,
it is not the only curative modality. In addition, median survival
times for patients in surgery only arms of randomized studies have
ranged from 11 to 18.6months only and 5-year survival rates of
16–32% (Walsh et al., 1996; Bosset et al., 1997; Kelsen et al., 1998,
2007; Medical Research Council Oesophageal Cancer Working
Group, 2002; Tepper et al., 2008). The necessity for surgery to be
performed in high-throughput centers has been well documented.
In addition, the technical reﬁnements and advances in postop-
erative care that have occurred in recent years have resulted in
concrete improvements in patient outcome (Altorki and Skinner,
2001; Whooley et al., 2001; Wouters et al., 2008). Notwithstanding
these real advances there are limits going forward to what surgical
resection alone can achieve. These limits primarily relate to dis-
ease biology and extent, i.e., the presence or absence of subclinical
micrometastatic disease. Over the course of the last two decades
the priority has been to establish a role for additional modalities
in the management of localized esophageal cancer. In this context
even the role of surgery itself has been a matter of debate.
NEO-ADJUVANT CHEMOTHERAPY
The rationale for the addition of chemotherapy to surgery is pri-
marily the eradication of presumptive micrometastatic disease.
The proof of principle for this strategy has been demonstrated
in several solid tumor types. Administering this chemotherapy in
advance of surgery has a number of potential advantages includ-
ing the following: earlier treatment against micrometastatic dis-
ease; potentially increased resectability; and proportion of R0 or
margin-negative resections; and better tolerability compared to
the postoperative period.
The Intergroup 0113 study (N = 443) compared immedi-
ate surgery with surgery that was preceded by three cycles of
chemotherapy (cisplatin and 5-ﬂuorouracil). In the chemotherapy
arm two additional cycles were given after surgery. Disappoint-
ingly there was no difference in median survival between the two
groups (16.1 vs. 14.9months; P = 0.53) nor in 2- and 5-year sur-
vival rates (Kelsen et al., 1998, 2007). This study conﬁrmed the
poor prognosis of patients who had an incomplete, R1 or R2 resec-
tion. Only patients who underwent R0 resection had a substantial
chance of long-term disease-free survival, although a small pro-
portion of patients (N = 9) who had an R1 resection appeared
to be “salvaged” by postoperative chemoradiation. Chemotherapy
did appear to decrease the R1 resection rate however. Probably
the most important observation from this study was that patients
who responded to chemotherapy had a superior outcome (median
survival 3 years) compared to those who did not respond, for
whom the median survival was not different to the surgery only
arm (1.1 and 1.3 years, respectively). Likewise a phase II study
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of preoperative chemotherapy in patients with resectable disease
(mostly adenocarcinoma) revealed a similar disparity in survival
in favor of thosewho showed clinical evidence of response to treat-
ment (median survival 63.4 vs. 21.5months in favor of responders,
P = 0.005; Pennathur et al., 2008).
A similar but larger (N = 802) study by the Medical Research
Council (MRC) in the UK provided a slightly different result
than the Intergroup trial. This study compared two cycles of neo-
adjuvant chemotherapy (again cisplatin and 5-ﬂuorouracil) plus
surgery with surgery alone in patients with localized disease (Med-
ical Research Council Oesophageal CancerWorking Group, 2002).
Patients who received chemotherapy had a higher complete resec-
tion rate (78 vs. 70%; P < 0.001) and here there was an overall
survival beneﬁt for patients receiving chemotherapy (HR, 0.78;
P = 0.003),which translated into an absolute beneﬁt in 5-year sur-
vival of 6% (23 vs. 17.1%). How does one reconcile the ostensibly
different outcomes in both the Intergroup and the MRC studies?
As mentioned above, it is likely that the beneﬁt of preoperative
chemotherapy is conﬁned to a select group of patients, i.e., those
who manifest a response. This was inferred by the updated results
of the Intergroup study but perhaps needed the larger numbers of
the MRC study to translate into a survival beneﬁt for the overall
chemotherapy cohort and result in a statistically positive study.
The other major applicable study evaluating the role of preop-
erative chemotherapy was the Medical Research Council Adju-
vant Gastric Cancer Infusional Chemotherapy (MAGIC) trial
(N = 503;Cunninghamet al., 2006).Althoughprimarily a studyof
gastric cancer∼25% had adenocarcinoma of the lower esophagus
or esophago-gastric junction and therefore this study is relevant to
this discussion. Chemotherapy consisted of cisplatin, ﬂuorouracil,
and epirubicin and was administered in a peri-operative fashion
(three cycles before and three cycles after surgery). Patients in the
control armunderwent surgery alone. Thedifﬁculty in administer-
ing postoperative treatment in this population was underlined by
the fact that only 42% of those assigned to the chemotherapy arm
completed postoperative treatment. In the chemotherapy group
the median diameter of resected tumors was smaller, there were
relativelymore T1 andT2 tumors and there was a trend toward less
of a nodal burden. This extended into a survival advantage (HR
for death= 0.75; 95% CI: 0.6–0.93; 5-year survival 36.3 vs. 23%,
P = 0.009). These results apply to the study population as a whole.
As determined in the subgroup analysis there was no evidence of
heterogeneity of treatment effect according to the site of the pri-
mary tumor (gastric vs. esophageal tumor). A similar result was
reported in a French study (N = 224) which evaluated preopera-
tive chemotherapy (cisplatin and 5-ﬂuorouracil) in patients with
adenocarcinoma of the stomach or lower esophagus (Boige et al.,
2007). Of the patients who were randomized to the chemother-
apy arm∼50% of them also received postoperative chemotherapy.
Preoperative chemotherapy was associated with an increased R0
rate (84 vs. 73%, P = 0.04) and improvements in 5-year disease-
free (34 vs. 21%) and overall survival (38 vs. 24%) in favor of the
chemotherapy arm.
It is unclear whether the relative importance of chemotherapy
differs according to histology. The MAGIC study was exclusively
in patients with adenocarcinoma and in the MRC study 66% had
adenocarcinoma. However the authors of the latter study point
out that the hazard ratios for treatment effect were the same for
both squamous and adenocarcinoma pathology (0.78) albeit with
different conﬁdence intervals.
The optimal timing for the peri-operative chemotherapy
administration was evaluated in a large prospective phase III
trial (N = 330) conducted by the Japan Clinical Oncology Group
(JCOG 9907). This trial was terminated early after it showed
an advantage beneﬁt of neo-adjuvant chemotherapy with cis-
platin plus 5-ﬂuorouracil (CF) compared to adjuvant CF for
stage II/III esophageal SCC. Patients who received neo-adjuvant
chemotherapy had a longer overall survival (OS; HR= 0.64, 95%
CI: 0.45–0.91, two-sided P = 0.014) with no increase in the risk
of complications or hospital mortality after surgery (Ando et al.,
2008; Hirao et al., 2011). Phase III trials that used neo-adjuvant
chemotherapy are summarized in Table 1.
CHEMORADIATION AS PRIMARY MODALITY OR BEFORE SURGERY
Combined chemoradiation became established in esophageal can-
cer as a result of the RTOG 85-01 study,which compared radiation
alone to chemotherapy plus radiation (Herskovic et al., 1992).
In this landmark study chemoradiation comprised four cycles of
combined 5-ﬂuorouracil (1000mg/m2 daily for 4 days) and cis-
platin (75mg/m2 on day 1) with 50Gy of radiation therapy, as
compared with a higher dose of radiation therapy (64Gy) alone.
The majority of patients (∼80%) had squamous cancer of the tho-
racic esophagus. Patients with gastric, mediastinal, or supraclav-
icular lymph nodes involvement were excluded. Median survival
was better for the chemoradiation group (12.5 vs. 8.9months) and
longer follow-up revealed the potential for long-term survival in
this disease even in the absence of surgical resection (5-year sur-
vival 26 vs. 0%; Cooper et al., 1999). A subsequent study addressed
the question of higher doses of radiation but this was not found
to be effective (Minsky et al., 2002). A major argument for the
incorporation of radiation therapy – as opposed to neo-adjuvant
chemotherapy alone as discussed in the previous section – is the
higher pathological complete response (pCR) rate that is achieved
and the correlation of this with survival (Berger et al., 2005; Don-
ahue et al., 2009). Chemoradiation has been associated with a pCR
rate of 20–30% but with chemotherapy alone this is extremely low
(<5%; MacGuill et al., 2006).
A logical extension from RTOG 85-01 was to see if the addition
of chemoradiation to surgery provided an additional beneﬁt com-
pared to surgery alone. Twometa-analyses have suggested a beneﬁt
for chemoradiation and surgery (so-called trimodality therapy)
compared to surgery alone (Urschel andVasan, 2003; Gebski et al.,
2007). Individual phase III studies however have been conﬂicting
with several randomized studies showing no beneﬁt (Bosset et al.,
1997; Urba et al., 2001; Burmeister et al., 2005) and three phase
III trials demonstrating a beneﬁt from trimodality therapy. The
ﬁrst positive study was reported by Walsh et al. and has been crit-
icized due to the poor survival of the surgery alone group (Walsh
et al., 1996; Ku and Ilson, 2008). The second positive study was
the CALGB 9781, which attempted to address the question in a
deﬁnitive fashion by randomizing patients to trimodality therapy
or surgery alone. Unfortunately, only 56 of a planned 475 patients
were enrolled (Tepper et al., 2008). Nevertheless the study was
well-designed, well-conducted, and showed a 5-year survival rate
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Table 1 | Phase III studies using neo-adjuvant chemotherapy.
Study N Study Population1 Treatment Result2
Intergroup 0113 (Kelsen et al.,
1998, 2007)
443 54% Adeno, 46% SCC Cis +5-FU x3Cy before
surgery followed by 2Cy after
surgery vs. surgery only
16.1 vs. 14.9m; P =0.53
MRC (Medical Research
Council Oesophageal Cancer
Working Group, 2002)
802 66% Adeno, 34% SCC Cis +5-FU x2Cy+ surgery vs.
surgery only
16.8 vs. 13.3m; P =0.003
MAGIC (Cunningham et al.,
2006)
503 Adeno, 25% lower
esophagus/EGJ
Peri-operative ECF3 + surgery
vs. surgery only
5 years survival 36 vs. 23% (95%
CI: 16.6–29.4)
Boige et al. (2007) 224 Predominant gastric but included
lower esophagus/EGJ
Cis +5-FU x2-3 Cy+ surgery
vs. surgery only
5 years survival 38 vs. 24%
JCOG 9907 (Ando et al.,
2008; Hirao et al., 2011)
330 SCC Cis +5-FU x2 Cy before or
after surgery
Neo-adjuvant chemo had superior
OS; HR=0.64 (95% CI: 0.45–0.91)
N, number of patients; Adeno, adenocarcinoma; SCC, squamous cell carcinoma; Cis, cisplatin; 5-FU, 5-ﬂurouracil; Cy, cycle; m, month; yr, year; EGJ, esophageal
gastric junction; OS, overall survival; RT, radiation therapy. 1Esophageal cancer unless stated. 2Median overall survival unless stated. 3Chemotherapy consisted of
three preoperative and three postoperative cycles of intravenous epirubicin 50mg/m2 and cisplatin 60mg/m2 on day 1, and a continuous intravenous infusion of
ﬂuorouracil 200mg/m2 for 21 days.
of 39% (95% CI: 21–57%) vs. 16% (95% CI: 5–33%) in favor
of trimodality therapy. The last study to show a beneﬁt from tri-
modality therapy compared to surgery alone was the CROSS trial
(N = 363). Patients on the CRT arm had higher R0 resection rate
(92.3 vs. 64.9%) and median overall survival [49 vs. 26months,
P = 0.011, HR 0.67 (95% CI: 0.50–0.92)] with no difference in
the postoperative mortality rate (Gaast et al., 2010). Notewor-
thy, patients on CRT arm received lower dose of RT compared to
CALGB 9781 trial (41.4 vs. 50.4Gy) administered concurrently
with weekly paclitaxel 50mg/m2 and carboplatin AUC= 2 for
5weeks. Another logical question deriving from RTOG 85-01 was
to question the added value of surgery given the potential and
ostensibly equivalent long-term survival rate with chemoradiation
alone. Stahl and colleagues addressed this question in an interest-
ing study in patients with squamous pathology. In this study all
patients received induction chemotherapy and chemoradiation,
the experimental question being the added role of surgery (Stahl
et al., 2005). Those who were randomized to the non-surgery arm
received a higher dose of radiation (65 vs. 40Gy). The results were
not clear-cut in that those who underwent surgery had better local
control but a higher treatment-related mortality. There was no
difference in overall survival.
Similarly Bedenne et al. (2007) compared surgery to additional
chemoradiation in a population of patients with predominantly
squamous cancer, all of whom received initial chemoradiation.
The essential feature in the design was that only patients who
showed evidence of clinical response to chemoradiation were ran-
domized to either surgery or continued chemoradiation. The
results were consistent with the Stahl study. 58% of patients
responded to chemoradiation and were randomized. There was no
difference in survival between the two arms. The 3-month mortal-
ity was less in the chemoradiation arm (0.8 vs. 9.3%, P = 0.002) at
the apparent expense of less local control (loco-regional recurrence
43 vs. 34%, respectively).
A consistent feature of studies in this disease indication has
been the relatively slow pace of clinical accrual. As seen in CALGB
9781 this results in well-designed but underpowered studies and
is a signiﬁcant barrier to advancement in the ﬁeld, particularly
in the era of targeted therapy. As an example FFCD9102 and
Stahl et al. (2005) studies required 8 and 9 years, respectively, to
accrue patients (Bedenne et al., 2007). Phase III trials that used
neo-adjuvant chemoradiation therapy are summarized in Table 2.
NEO-ADJUVANT CHEMORADIATION VS. NEO-ADJUVANT
CHEMOTHERAPY
Stahl et al. (2009) attempted to compare the two compet-
ing neo-adjuvant approaches in a phase III randomized study
of chemotherapy (consisting of cisplatin and ﬂuorouracil) vs.
chemoradiation, followed by surgery. Chemoradiation comprised
a lower dose (30Gy) of radiation than usual given over a shorter
period (3weeks) in association with cisplatin and etoposide.
Unfortunately accrual was slow and the study was closed early
with 119 patients treated. Nevertheless the results are an impor-
tant addition to the ﬁeld. Patients who received chemoradiation
had a signiﬁcant higher probability achieving a pCR (15.6 vs. 2%)
and proportionally higher N0 rate (64.4 vs. 37.7%) at resection.
In addition, preoperative chemoradiation therapy was associated
with an improved 3-year survival rate (47.4 vs. 27.7%, log-rank
P = 0.07), although this was not statistically signiﬁcant. The other
feature of this study was the homogeneity of the study popula-
tion conﬁned as it was to patients with adenocarcinoma of the
esophago-gastric junction.
NEWER CHEMO REGIMENS
The MUNICON-2 study illustrates the need for more effective
treatments given the dismal outcome of patients who received
salvage treatment. In the vast majority of neo-adjuvant stud-
ies cisplatin and ﬂuorouracil have been the agents used either
alone or with radiation. Oxaliplatin is another platinum agent that
was investigated in a phase II study by the Southwestern Oncol-
ogy Group (SWOG) in combination with infusional ﬂuorouracil
revealing an impressive pCR rate of 33% (Leichman et al., 2009).
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Table 2 | Phase III studies using neo-adjuvant chemoradiation therapy.
Study N Study Population1 Treatment Result2
RTOG-8501 (Herskovic et al.,
1992; Cooper et al., 1999)
196 80% SSC, 20% Adeno Cis +5-FU x4Cy+RT (50Gy) vs. RT
(64Gy) only
12.5 vs. 8.9m; P <0.001
5 years survival 26 vs. 0%
Walsh et al. (1996) 113 Adeno Cis +5-FU x2Cy+RT (40Gy)+ surgery
vs. surgery only
3 year survival 32 vs. 6%;
P =0.001
CALGB 9781 (Tepper et al.,
2008)
56 Esophagus/EGJ/cardia 75%
adeno, 25% SCC
Cis +5-FU x2Cy+RT
(50.4Gy)+ surgery vs. surgery only
5 years survival 39 vs.
16%; P =0.002
Bosset et al. (1997) 282 SCC Cis x2Cy+RT (37Gy)+ surgery vs.
surgery only
18.6m in both arms
Burmeister et al. (2005) 256 63% Adeno, 37% SCC Cis +5-FU x1Cy+RT (35Gy)+ surgery
vs. surgery only
22.2 vs. 19.3m; P =0.57
Stahl et al. (2005) 172 SCC Induction chemo+ chemoRT+ surgery
vs. induction chemo+ chemoRT3
16.4 vs. 14.9m; P <0.05
FFCD 9102(Bedenne et al.,
2007)
444 89% SCC, 11% Adeno Cis +5-FU x2Cy+RT (46Gy).
Responders randomized to surgery or
more chemoRT
17.7 vs. 19.3m; P =0.44
CROSS (Gaast et al., 2010) 363 Esophagus/EGJ 75% Adeno,
25% SCC
Paclitaxel/carboplatin x5Cy+RT
(41.4Gy)+ surgery vs. surgery only
49 vs. 26m; P =0.011
N, number of patients; Adeno, adenocarcinoma; SCC, squamous cell carcinoma; Cis, cisplatin; 5-FU, 5-ﬂurouracil; Cy, cycle; m, month; yr, year; EGJ, esophageal gastric
junction; OS, overall survival; RT, radiation therapy. 1Esophageal cancer unless stated. 2Median overall survival unless stated. 3Induction chemotherapy comprised:
ﬂuorouracil 500mg/m2, leucovorin 300mg/m2, etoposide 100mg/m2, and cisplatin 30mg/m2 on days 1–3 every 3weeks; chemoRT comprised cisplatin 50mg/m2 on
days 2 and 8 and etoposide 80mg/m2 on days 3–5 concomitant with radiotherapy.
Moreover, several phase II studies have demonstrated the feasibil-
ity and efﬁcacy of various schedules of paclitaxel in combination
with platinum agents showing impressive pCR rates (Blanke et al.,
1999;Meluch et al., 2003;Urba et al., 2003; Brenner et al., 2004; van
Meerten et al., 2006; van de Schoot et al., 2008). Likewise the addi-
tion of docetaxel to cisplatin and 5-FU (DCF) was found to be well
tolerated with a pCR rate of 47%, a 3 year survival of 81% (Pasini
et al., 2009), and an overall response of 60% (Hara et al., 2011).
Adding docetaxel to cisplatin and capecitabine (DCX) also resulted
in tumor downstaging in 56% of patients (Fonseca et al., 2011)
and successful R0 resection in 90% of patients (Thuss-Patience
et al., 2011). Furthermore, many trials had compared the efﬁcacy
of different chemotherapy combinations. Recently the regimen of
FOLFOX4 was compared to cisplatin and 5-FU, both combined
with radiation therapy. FOLOFOX4 was found to have a higher
response rate (45 vs. 29%), which translated to a longer overall
survival (22.7 vs. 15.1months). This regimen is now being tested
in a phase III trial (Conroy et al., 2010). Another randomized
phase II study (ECOG 1201) compared paclitaxel/cisplatin-based
and irinotecan/cisplatin-based chemoradiation. Pathological CR
rates were reasonable, 16 and 14%, respectively (Kleinberg et al.,
2007). Survival was similar for both treatment arms and did not
appear to be better compared to the historical experience e with
cisplatin/5-FU (Kleinberg et al., 2008).
TARGETED THERAPY
Many targeted therapies have been recently investigated in
advanced esophageal cancer showing an encouraging efﬁcacy that
still needs to be validated. Approximately 50–70% of esophageal
cancers have an overexpression of the EGFR protein, how-
ever based on the experience of other malignancies, this is not
necessarily predictive of response. Moreover, the incidence of
KRAS mutations in junctional or gastric adenocarcinoma (6–
21%) and in esophageal squamous cancer (16% in one report)
appears to be less than in colon cancer where these mutations
are predictive of resistance to cetuximab (Sommerer et al., 2004;
Lyronis et al., 2008). Accordingly, the role of cetuximab – a mon-
oclonal antibody directed against EGFR – needs to be clariﬁed.
The use of cetuximab in the neo-adjuvant setting with radiation
in esophageal cancer appears to be feasible and to provide good
overall response rate (66.6–80%) and pCR rate (36%; Agarwala
et al., 2009; Ruhstaller et al., 2009; Dahan et al., 2011; Sunpaw-
eravong et al., 2011). In addition, the combination of FOLFIRI
and cetuximab showed an impressive survival of 16months (Pinto
et al., 2007) in patients with untreated advanced gastric or gastro-
esophageal junction (GEJ) adenocarcinoma. Currently, the RTOG
is evaluating cetuximab in combination with cisplatin, paclitaxel,
and radiation in esophageal cancer. Another EGFR targeted ther-
apy, panitumumab, is currently being assessed in the REAL3 trial
in combination with chemotherapy (epirubicin, oxaliplatin, and
capecitabine).
HER-2 overexpression as detected by immunohistochemistry
ranges from 19 to 43% but in contrast to breast cancer, HER-
2-positive status in esophageal adenocarcinoma is not an inde-
pendent prognostic factor (Shah et al., 2011a; Yoon et al., 2011).
The efﬁcacy of trastuzumab, a monoclonal antibody directed
against HER-2, in advanced gastric cancer, and GEJ cancer was
recently reported in the ToGA trial. Patients (N = 298) treated
with trastuzumab in combination with capecitabine plus cisplatin
had a longer OS of 13.8months compared to 11.1months in
patients (N = 296) treated with the same chemotherapy regimen
alone (P = 0.0046; Bang et al., 2010).
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Blocking the tumor angiogenesis is another strategy that has
been extensively investigated in cancer including esophageal can-
cer. Bevacizumab, a humanized monoclonal antibody that inhibits
the vascular endothelial growth factor A (VEGF-A), has been
shown to be active in some studies in esophageal cancer. A phase
II study of bevacizumab in combination with irinotecan and
cisplatin in patients with advanced gastric or junctional adenocar-
cinomademonstrated the safety of this approach and an encourag-
ing efﬁcacy (Shah et al., 2006; Ilson et al., 2009). Likewise the addi-
tion of Bevacizumab to docetaxel, cisplatin, and 5-FU appeared to
be tolerable with promising response rate of 85% in GEJ tumors
(Shah et al., 2011b). Although the addition of Bevacizumab to
chemotherapy with capecitabine or 5-FU and cisplatin in theAVA-
GAST trial (N = 774) resulted in a signiﬁcant improvement in
overall response rate (37.4–46%) and PFS (5.3–6.7months) in
patients with advanced gastric or GEJ adenocarcinoma, this trial
failed to meet its primary endpoint of prolonging OS (12.1 vs.
10.1months, HR 0.87; P = 0.1002; Ohtsu et al., 2011). However,
the authors argued that American patients demonstrated signif-
icantly improved OS (HR 0.63), while Asian region patients did
not (HR 0.97; Shah et al., 2012). This regional variation in ben-
eﬁt is still to be further studied in future trials. Nonetheless, the
applicability of bevacizumab to esophageal cancer will be at least
partially answered by the MAGIC-B study in the UK evaluating
this agent in combination with epirubicin/cisplatin/capecitabine
(ECX) chemotherapy in junctional or gastric adenocarcinoma.
Other targeted agents such as sunitinib and sorafenib are cur-
rently being studied in esophageal cancer (Ilson et al., 2011; Knox
et al., 2011)
CONCLUSION/FUTURE PERSPECTIVES
Amidst the confusion of the phase III studies in locally advanced
esophageal cancer over the past decade – and from which no clear
standard of care has emerged – one theme is recurrent: patients
who respond to neo-adjuvant therapy have a far superior survival
than those who do not.
Whilst the so-called targeted agents have yet to be evaluated
in the phase III setting it is unlikely that this central problem
will have changed, i.e., trying to prospectively identify those who
will beneﬁt from neo-adjuvant therapy and those who will not.
Although we have an increasing number of active agents in this
disease we remain in the dark ages in terms of our ability to predict
what will work and what will not. In esophageal cancer we do not
have a single predictive marker that is of use to the clinician. Even
the chief differentiating factor – squamous vs. adenocarcinoma– is
of little help in the clinic in dictating therapy choices. Differential
gene expression proﬁling has the potential to better categorize
esophageal cancer in terms of its biology and response to therapy
(Hammoud et al., 2009). In correlative studies as part of the ECOG
1201 study mentioned above, analysis of single nucleotide poly-
morphisms in DNA repair pathways to seek predictors of response
identiﬁed an allele associated with a lower likelihood of pCR. It
is hoped that the accumulation of this type of information will
lead us to molecularly directed therapy for individual patients.
However the MUNICON-2 study underlines the fact that whilst
predictive biomarkers may help us to better direct care and pro-
vide us with a better indicator of prognosis, newer more effective
therapies are ultimately required to capitalize on this knowledge.
One of the difﬁculties with interpreting the data in esophageal
cancer has been the heterogeneity of diseases included. Eligibil-
ity criteria have tended to cross histological boundaries (squa-
mous vs. adenocarcinoma). Even where accrual is conﬁned to
adenocarcinoma, as in the MAGIC study, tumors from differ-
ent geographical locations have been mixed together. There is a
considerable difference between adenocarcinoma of the stom-
ach, lower esophagus, and esophago-gastric junction in terms
of molecular characteristics, pattern of spread and pre-disposing
risk factors (Tepper and O’Neil, 2009). Even within junctional
tumors there is a marked difference in terms of behavior and
these tumors have been classiﬁed accordingly (Siewert and Stein,
1998). Nonetheless, the majority of the clinical trials conducted
in locally advanced esophageal cancer were underpowered due to
poor accrual, which remains a challenge facing the ongoing and
future trials.
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